Abstract
Background
The underlying etiology of juvenile dermatomyositis (JDM) is unknown. T cell deficiency as well as Epstein–Barr virus (EBV) infection had been suspected to be involved in the pathogenesis, but it has been poorly evaluated in JDM patients.
Methods
This study described the traits of T and B lymphocyte subsets in newly onset JDM patients and the incidence of EBV infection in JDM patients compared with match controls. Newly developed JDM patients from 2014 to 2018 were included in the study. Lymphocytes with different markers (CD3+, CD3+CD4+, CD3+CD8+, CD3−CD19+ and CD3−CD16+CD56+) were tested with flow cytometry in the first admission or after 6 months of treatment. Statistical analysis was conducted to compare the EBV infection in the group of JDM patients and controls.
Results
We observed that JDM patients had higher positive rate of Epstein–Barr nuclear antigen-immunoglobulin G (IgG) (P < 0.0001) as well as EBV capsid antigen-IgG (P < 0.05) than normal controls. CD3−CD16+CD56+ lymphocyte was found to be extremely low in early stage of JDM patients, but increased after 6 months of treatment (P = 0.0091).
Conclusions
The level of CD3−CD16+CD56+ cells may associate with the clinical course of JDM. EBV may act as an environmental factor predisposing patients to the development of JDM.
Similar content being viewed by others
References
Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49:300–5.
Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280:24–38.
Huber AM. Juvenile dermatomyositis advances in pathogenesis, evaluation, and treatment. Pediatr Drugs. 2009;11:361–74.
Mamyrova G, O'Hanlon TP, Monroe JB, Carrick DM, Malley JD, Adams S, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum. 2006;54:3979–87.
Wedderburn LR, McHugh N, Chinoy H, Cooper RG, Salway F, Ollier WE, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford). 2007;46:1786–9.
Orione MA, Silva CA, Sallum AM, Campos LM, Omori CH, Braga AL, et al. Risk factors for juvenile dermatomyositis: exposure to tobacco and air pollutants during pregnancy. Arthritis Care Res (Hoboken). 2014;66:1571–5.
Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya JM, Shoenfeld Y. Epstein–Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci. 2007;1108:567–77.
Dietzman DE, Schaller JG, Ray CG, Reed ME. Acute myositis associated with influenza B infection. Pediatrics. 1976;57:255–8.
Broccolo F, Drago F, Cassina G, Fava A, Fusetti L, Matteoli B, et al. Selective reactivation of human herpesvirus 6 in patients with autoimmune connective tissue diseases. J Med Virol. 2013;85:1925–34.
Shirasaki F, Taniuchi K, Matsushita T, Hamaguhi Y, Takata M, Takehara K. Epstein–Barr virus-associated T-cell lymphoma: a case of eyelid swelling and intramuscular infiltration mimicking dermatomyositis. Br J Dermatol. 2002;147:1244–8.
Pender MP. CD8+ T-cell deficiency, Epstein–Barr virus infection, vitamin D deficiency, and steps to autoimmunity: a unifying hypothesis. Autoimmune Dis. 2012;2012:189096.
Garzelli C, Taub FE, Schaff JE, Prabhakar BS, Ginsberg-Fellner F, et al. Epstein–Barr virus transformed lymphocytes produce monoclonal autoantibodies that react with antigens in multiple organs. J Virol. 1984;52:722–5.
Ernste FC, Crowson CS, de Padilla CL, Hein MS, Reed AM. Longitudinal peripheral blood lymphocyte subsets correlate with decreased disease activity in juvenile dermatomyositis. J Rheumatol. 2013;40:1200–11.
Piper CJM, Wilkinson MGL, Deakin CT, Otto GW, Dowle S, Duurland CL, et al. CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through Toll-like receptor 7 and interferon-α. Front Immunol. 2018;6:1372.
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–7.
Hashimoto Y, Nawata Y, Kurasawa K, Takabayashi K, Oda K, Mikata A, et al. Investigation of EB virus and cytomegalovirus in rapidly progressive interstitial pneumonitis in polymyositis/dermatomyositis by in situ hybridization and polymerase chain reaction. Clin Immunol Immunopathol. 1995;77:298–306.
Brink AA, Meijer CJ, Nicholls JM, Middeldorp JM, van den Brule AJ. Activity of the EBNA1 promoter associated with lytic replication (Fp) in Epstein–Barr virus associated disorders. Mol Pathol. 2001;54:98–102.
Allday MJ, Crawford DH, Griffin BE. Epstein–Barr virus latent gene expression during the initiation of B cell immortalization. J Gen Virol. 1989;70:1755–64.
Lünemann JD, Jelcić I, Roberts S, Lutterotti A, Tackenberg B, Martin R, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med. 2008;205:1763–73.
Füst G. The role of the Epstein–Barr virus in the pathogenesis of some autoimmune disorders—similarities and differences. Eur J Microbiol Immunol (Bp). 2013;1:267–78.
Cornaby C, Gibbons L, Mayhew V, Taylor-Albert E, Lehman TJ, Harley JB. B cell epitope spreading: mechanisms and contribution to autoimmune diseases. Immunol Lett. 2014;163:56–68.
James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein–Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest. 1997;15:3019–26.
Miller ML, Lantner R, Pachman LM. Natural and antibody-dependent cellular cytotoxicity in children with systemic lupus erythematosus and juvenile dermatomyositis. J Rheumatol. 1983;10:640–2.
Acknowledgements
We are very grateful to the Leukemia Lab of Children’s Hospital of Zhejiang University School of Medicine for flow cytometry. We also want to thank all participating patients and volunteers for their support.
Funding
This work was supported by Zhejiang Medical and Health Science and Technology Project (No. 2017KY440).
Author information
Authors and Affiliations
Contributions
QZ contributed to manuscript writing. KZ contributed to histopathological examination. CNG contributed to statistical analysis. YPX contributed to sample collection and patient informed consent. MPL contributed to paper editing. All authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
Ethical approval
The study was approved by the pediatric review board committee (approval number: 2019-IRB-099), and informed consent from patients and healthy individuals was acquired before the study.
Conflict of interest
No financial or nonfinancial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zheng, Q., Zhu, K., Gao, CN. et al. Prevalence of Epstein–Barr virus infection and characteristics of lymphocyte subsets in newly onset juvenile dermatomyositis. World J Pediatr 17, 205–209 (2021). https://doi.org/10.1007/s12519-019-00314-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-019-00314-7